These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38869181)

  • 21. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.
    Beltran H; Rickman DS; Park K; Chae SS; Sboner A; MacDonald TY; Wang Y; Sheikh KL; Terry S; Tagawa ST; Dhir R; Nelson JB; de la Taille A; Allory Y; Gerstein MB; Perner S; Pienta KJ; Chinnaiyan AM; Wang Y; Collins CC; Gleave ME; Demichelis F; Nanus DM; Rubin MA
    Cancer Discov; 2011 Nov; 1(6):487-95. PubMed ID: 22389870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Icaritin suppresses development of neuroendocrine differentiation of prostate cancer through inhibition of IL-6/STAT3 and Aurora kinase A pathways in TRAMP mice.
    Sun F; Zhang ZW; Tan EM; Lim ZLR; Li Y; Wang XC; Chua SE; Li J; Cheung E; Yong EL
    Carcinogenesis; 2016 Jul; 37(7):701-711. PubMed ID: 27207661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network.
    Lee AR; Gan Y; Tang Y; Dong X
    EBioMedicine; 2018 Sep; 35():167-177. PubMed ID: 30100395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative study of neuroendocrine acquisition and biomarker expression between neuroendocrine and usual prostatic carcinoma.
    Xiao GQ; Ho G; Suen C; Hurth KM
    Prostate; 2021 Jun; 81(8):469-477. PubMed ID: 33848377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ONECUT2 is a driver of neuroendocrine prostate cancer.
    Guo H; Ci X; Ahmed M; Hua JT; Soares F; Lin D; Puca L; Vosoughi A; Xue H; Li E; Su P; Chen S; Nguyen T; Liang Y; Zhang Y; Xu X; Xu J; Sheahan AV; Ba-Alawi W; Zhang S; Mahamud O; Vellanki RN; Gleave M; Bristow RG; Haibe-Kains B; Poirier JT; Rudin CM; Tsao MS; Wouters BG; Fazli L; Feng FY; Ellis L; van der Kwast T; Berlin A; Koritzinsky M; Boutros PC; Zoubeidi A; Beltran H; Wang Y; He HH
    Nat Commun; 2019 Jan; 10(1):278. PubMed ID: 30655535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding the function of Pax5 in development of docetaxel-resistant neuroendocrine-like prostate cancers.
    Bhattacharya S; Harris HL; Islam R; Bodas S; Polavaram N; Mishra J; Das D; Seshacharyulu P; Kalluchi A; Pal A; Kohli M; Lele SM; Muders M; Batra SK; Ghosh PM; Datta K; Rowley MJ; Dutta S
    Cell Death Dis; 2024 Aug; 15(8):617. PubMed ID: 39183332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
    Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
    BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SOX2 has dual functions as a regulator in the progression of neuroendocrine prostate cancer.
    Li H; Wang L; Li Z; Geng X; Li M; Tang Q; Wu C; Lu Z
    Lab Invest; 2020 Apr; 100(4):570-582. PubMed ID: 31772313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Roles of Alternative RNA Splicing of the Bif-1 Gene by SRRM4 During the Development of Treatment-induced Neuroendocrine Prostate Cancer.
    Gan Y; Li Y; Long Z; Lee AR; Xie N; Lovnicki JM; Tang Y; Chen X; Huang J; Dong X
    EBioMedicine; 2018 May; 31():267-275. PubMed ID: 29759485
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Bhagirath D; Yang TL; Tabatabai ZL; Majid S; Dahiya R; Tanaka Y; Saini S
    Clin Cancer Res; 2019 Nov; 25(21):6532-6545. PubMed ID: 31371344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuropilin-2 promotes lineage plasticity and progression to neuroendocrine prostate cancer.
    Wang J; Li J; Yin L; Pu T; Wei J; Karthikeyan V; Lin TP; Gao AC; Wu BJ
    Oncogene; 2022 Sep; 41(37):4307-4317. PubMed ID: 35986103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer.
    Ci X; Hao J; Dong X; Choi SY; Xue H; Wu R; Qu S; Gout PW; Zhang F; Haegert AM; Fazli L; Crea F; Ong CJ; Zoubeidi A; He HH; Gleave ME; Collins CC; Lin D; Wang Y
    Cancer Res; 2018 May; 78(10):2691-2704. PubMed ID: 29487201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer.
    Flores-Morales A; Bergmann TB; Lavallee C; Batth TS; Lin D; Lerdrup M; Friis S; Bartels A; Kristensen G; Krzyzanowska A; Xue H; Fazli L; Hansen KH; Røder MA; Brasso K; Moreira JM; Bjartell A; Wang Y; Olsen JV; Collins CC; Iglesias-Gato D
    Clin Cancer Res; 2019 Jan; 25(2):595-608. PubMed ID: 30274982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenomic Landscape of Neuroendocrine Prostate Cancer.
    Bhinder B; Ferguson A; Sigouros M; Uppal M; Elsaeed AG; Bareja R; Alnajar H; Eng KW; Conteduca V; Sboner A; Mosquera JM; Elemento O; Beltran H
    Clin Cancer Res; 2023 Aug; 29(15):2933-2943. PubMed ID: 37223924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic and epigenetic features of neuroendocrine prostate cancer and their emerging applications.
    Zhang X; Barnett E; Smith J; Wilkinson E; Subramaniam RM; Zarrabi A; Rodger EJ; Chatterjee A
    Int Rev Cell Mol Biol; 2024; 383():41-66. PubMed ID: 38359970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reciprocal YAP1 loss and INSM1 expression in neuroendocrine prostate cancer.
    Asrani K; Torres AF; Woo J; Vidotto T; Tsai HK; Luo J; Corey E; Hanratty B; Coleman I; Yegnasubramanian S; De Marzo AM; Nelson PS; Haffner MC; Lotan TL
    J Pathol; 2021 Dec; 255(4):425-437. PubMed ID: 34431104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Smoothened loss is a characteristic of neuroendocrine prostate cancer.
    Wang L; Li H; Li Z; Li M; Tang Q; Wu C; Lu Z
    Prostate; 2021 Jun; 81(9):508-520. PubMed ID: 33955576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4.
    Coleman DJ; Sampson DA; Sehrawat A; Kumaraswamy A; Sun D; Wang Y; Schwartzman J; Urrutia J; Lee AR; Coleman IM; Nelson PS; Dong X; Morrissey C; Corey E; Xia Z; Yates JA; Alumkal JJ
    Neoplasia; 2020 Jun; 22(6):253-262. PubMed ID: 32403054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imatinib Spares cKit-Expressing Prostate Neuroendocrine Tumors, whereas Kills Seminal Vesicle Epithelial-Stromal Tumors by Targeting PDGFR-β.
    Jachetti E; Rigoni A; Bongiovanni L; Arioli I; Botti L; Parenza M; Cancila V; Chiodoni C; Festinese F; Bellone M; Tardanico R; Tripodo C; Colombo MP
    Mol Cancer Ther; 2017 Feb; 16(2):365-375. PubMed ID: 27980106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spatial Gene Expression Analysis Reveals Characteristic Gene Expression Patterns of De Novo Neuroendocrine Prostate Cancer Coexisting with Androgen Receptor Pathway Prostate Cancer.
    Watanabe R; Miura N; Kurata M; Kitazawa R; Kikugawa T; Saika T
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.